**World Is Now One Step Closer to Ending the HIV Epidemic**
*By Dwaipayan Roy | Sep 24, 2025, 08:00 PM*
—
A groundbreaking development in the fight against HIV/AIDS has brought the world closer to ending the epidemic. A new injectable drug called **Lenacapavir**, which prevents HIV infection, will soon be made available at an affordable price in over 100 low-income countries. This significant move is expected to provide millions with access to breakthrough treatment and drastically reduce new infections worldwide.
### What is Lenacapavir?
Lenacapavir is an innovative injectable drug that prevents the replication of the HIV virus inside cells. Endorsed by the World Health Organization (WHO) in July, this long-acting injection offers six months of protection against HIV infection per dose, administered just twice yearly.
The drug’s long-lasting effect makes it especially beneficial for vulnerable populations, including adolescent girls and young women, members of the LGBT community, sex workers, and drug users — groups often at higher risk of HIV infection.
### Affordable Access: A Game Changer
Currently, Lenacapavir is priced at $28,000 per person annually, making it inaccessible for many in low-income regions. However, thanks to an agreement brokered by former U.S. President Bill Clinton, the drug will be available for just $40 per person annually by 2027.
This deal was achieved through negotiations involving the Clinton Foundation, the Gates Foundation, and other key organizations such as South Africa’s Wits Research Institute (Wits RHI). The generic version awaits regulatory approval but is expected to launch within the next 18 months.
### Dual Use: Prevention and Treatment
Lenacapavir’s potential extends beyond prevention. It can also be used to treat people already living with HIV, enhancing its value as a versatile tool in global HIV management.
Studies indicate that making Lenacapavir available to just 4% of the population could prevent up to 20% of new HIV infections, underlining its critical role in curbing the epidemic.
### Impact on Global Health and Key Regions
The announcement of affordable access to Lenacapavir comes during a challenging period for global health. Despite progress since 2000, approximately 1.3 million people were newly infected with HIV last year, and over 600,000 died from AIDS-related illnesses.
South Africa, which carries the highest burden with nearly eight million people living with HIV, will be among the first countries to receive the new affordable treatment. This access has the potential to transform HIV prevention and care in the region substantially.
—
With Lenacapavir’s arrival on the horizon, the world moves closer to a future where HIV/AIDS can be effectively controlled and ultimately ended. This advancement exemplifies the power of collaboration and innovation in addressing one of the most persistent global health challenges.
https://www.newsbytesapp.com/news/science/new-hiv-prevention-injection-to-cost-just-40/story
Be First to Comment